Predict your next investment

Angel Investor (Individual)

See what CB Insights has to offer

Investments

3

Portfolio Exits

1

About Belinda Termeer

Belinda Termeer is the widow of Henri Termeer.

Belinda Termeer Headquarter Location

Massachusetts,

United States

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest Belinda Termeer News

PIC Therapeutics Raises $5M in Seed Funding

Apr 15, 2020

PIC Therapeutics , a Boston, MA-based biotechnology company focused on transforming the treatment of cancer though the selective modulation of oncogene translation, closed a $5M seed equity funding. The round was led by Advent Life Sciences with participation from Belinda Termeer, widow of Genzyme CEO Henri Termeer, as well as several biopharmaceutical industry executives and other individual investors. The company intends to use the funds to advance its development ettorts. Led by Sun Altbach, CEO, PIC Therapeutics is a biotechnology company focused on developing a new generation of therapeutics based on the modulation of RNA translation. PIC’s therapeutics target the “master switch” of cancer signaling pathways, selectively blocking oncogene protein production by modulating the Pre-Initiation Complex (PIC) that drives their mRNA translation. The company was founded based on the extensive research of scientific founder Professor Gerhard Wagner of Harvard University and is led by founding CEO Sun Altbach, a 20+ year life sciences veteran and by Dr. Alan Walts, Executive Chairman and Venture Partner at Advent Life Sciences. PIC’s Board of Directors consists of: Alan Walts, PhD, Executive Chairman of the Board; Venture Partner, Advent Life Sciences Sun Altbach, MBA, CEO and President, PIC Therapeutics Richard Peters, MD, PhD, Co-Founder, PIC Therapeutics; CEO Yumanity Therapeutics Belinda Termeer, Termeer Foundation Gerhard Wagner,PhD, Co-Founder, PIC Therapeutics; Elkan Rogers Blout Professor of Biological Chemistry and Molecular Pharmacology, Harvard Medical School PIC’s Scientific and Corporate Advisory Board consists of: Keith Flaherty, MD, Director of Clinical Research at the Cancer Center at MGH Jennifer Petter, PhD, Founder and Chief Scientific Officer of Arrakis Therapeutics Nahum Sonenberg, PhD, Biochemistry Professor and Gilman Cheney Chair, McGill University Yat Sun Or, PhD, Chief Scientific Officer, Enanta Pharmaceuticals Jan Van Heek, MBA, Board Member, Amarin Corporation and Minerva Neuroscience Gerhard Wagner,PhD, Co-Founder, PIC Therapeutics; Elkan Rogers Blout Professor of Biological Chemistry and Molecular Pharmacology, Harvard Medical School FinSMEs

Belinda Termeer Investments

3 Investments

Belinda Termeer has made 3 investments. Their latest investment was in Artax Biopharma as part of their Series C on January 1, 2022.

CBI Logo

Belinda Termeer Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

1/3/2022

Series C

Artax Biopharma

$26M

Yes

4

7/20/2021

Series C

Subscribe to see more

$99M

Subscribe to see more

10

4/15/2020

Seed VC

Subscribe to see more

$99M

Subscribe to see more

10

Date

1/3/2022

7/20/2021

4/15/2020

Round

Series C

Series C

Seed VC

Company

Artax Biopharma

Subscribe to see more

Subscribe to see more

Amount

$26M

$99M

$99M

New?

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

4

10

10

Belinda Termeer Portfolio Exits

1 Portfolio Exit

Belinda Termeer has 1 portfolio exit. Their latest portfolio exit was Amylyx Pharmaceuticals on January 07, 2022.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

1/7/2022

IPO

$99M

Public

6

Date

1/7/2022

Exit

IPO

Companies

Valuation

$99M

Acquirer

Public

Sources

6

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.